Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Vaccine committee votes to scrap universal hepatitis B shots for newborns despite outcry from children’s health experts - 2Bombardier Global 8000 Enters Service
- 3China's 'Venice Of The East' Is A Historic Canal City Near Shanghai With Arched Bridges And Lantern-Lit Waterways
- 4Hitler's madcap mega-railway would have linked Berlin with India
- 5Top Smoothie Flavor: What's Your Mix?
- Chinese astronauts’ return to Earth delayed over fears spaceship damaged by debris
- Instructions to Expand Your Advantages from an Open Record Reward
- Are protests pushing Iran's Islamic regime toward a tipping point?
- Which '80s Film Actually Holds Up Today?
- Experience Unrivaled Sound: Top Speakers You Really want to Hear
- German Winemakers Rewrite The Rules Of Riesling In A Warming World
- Court clears Beersheba assault suspect of link to Haymanut Kasau disappearance, extends detention
- Famous Rough terrain Vehicles for 2024
- IDF: Staying in West Bank refugee camps will quell lone-wolf terror
